Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

Abstract

Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).